Aptalis

Template:Short description {{#invoke:Infobox|infobox}}Template:Template otherTemplate:Main other{{#invoke:Check for clobbered parameters|check|nested=1|template=Infobox company|cat=Template:Main other|name; company_name|logo; company_logo|logo_alt; alt|trade_name; trading_name|former_names; former_name|type; company_type|predecessors; predecessor|successors; successor|foundation; founded|founders; founder|defunct; dissolved|hq_location; location|hq_location_city; location_city|hq_location_country; location_country|num_locations; locations|areas_served; area_served|net_income; profit|net_income_year; profit_year|owners; owner |homepage; website }}{{#invoke:Check for unknown parameters|check|unknown=Template:Main other|preview=Page using Template:Infobox company with unknown parameter "_VALUE_" | ignoreblank=y | alt | area_served | areas_served | assets | assets_year | aum | brands | company_logo | company_name | company_type | defunct | dissolved | divisions | embed | equity | equity_year | fate | footnotes | former_name | former_names | foundation | founded | founder | founders | genre | homepage | hq_location | hq_location_city | hq_location_country | incorporated | image | image_alt | image_caption | image_size | image_upright | income_year | industry | ISIN | key_people | location | location_city | location_country | locations | logo | logo_alt | logo_caption | logo_class | logo_size | logo_upright | members | members_year | module | name | native_name | native_name_lang | net_income | net_income_year | num_employees | num_employees_year | num_locations | num_locations_year | operating_income | owner | owners | parent | predecessor | predecessors | production | production_year | products | profit | profit_year | rating | ratio | revenue | revenue_year | romanized_name | services | subsid | successor | successors | traded_as | trade_name | trading_name | type | website| qid | fetchwikidata | suppressfields | noicon | nocat | demo | categories }} Aptalis Pharma Inc. was a company in the pharmaceutical industry. In January 2014, the company was acquired by Forest Laboratories (acquired by Allergan) for $675 million. Through a series of acquisitions, the company is now a contract development and manufacturing organization and rebranded as Adare Phama Solutions, headquartered in Lawrenceville, New Jersey.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

History

Merger of predecessor companies: Axcan and Eurand

Axcan specialized in the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008.<ref>Template:Cite press release</ref> Eurand Pharmaceuticals was a producer and contract manufacturer of sustained release dosage forms or taste-masked pharmaceutical dosage forms. Both Axcan and Eurand produced and marketed versions of the drug pancrelipase, which is used in the treatment of symptoms related to cystic fibrosis.

In 2011, Eurand Pharmaceuticals and Axcan Pharma merged to form Aptalis.<ref>Template:Cite press release</ref>

Product launches

In June 2011, the company received approval from the Food and Drug Administration to sell a low strength version of ZENPEP (pancrelipase) capsules formulated for infants with exocrine pancreatic insufficiency due to cystic fibrosis.<ref>Template:Cite press release</ref>

On January 9, 2012, the company announced an agreement to market RECTIV, an ointment for the treatment of anal fissure, in the United States.<ref>Template:Cite press release</ref>

On January 18, 2012, the company announced that its partner, Gilead Sciences, received approval for the oral powder formulation of Viread (tenofovir disoproxil).<ref>Template:Cite press release</ref>

On September 3, 2013, the company launched PYLERA capsules (Bismuth subcitrate/metronidazole/tetracycline), which, in combination with omeprazole, is indicated for the treatment of patients with helicobacter pylori infections.<ref>Template:Cite press release</ref>

Acquisition of the company by Forest Laboratories

In January 2014, Forest Laboratories (now part of Allergan) announced that it had agreed to acquire Aptalis for $2.9 billion in cash.<ref>Template:Cite press release</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Aptalis withdrew its planned initial public offering after the announcement.<ref>Template:Cite news</ref>

In April 2015, TPG Capital acquired Aptalis Pharmaceutical Technologies and the company was renamed Adare Pharmaceuticals.<ref>Template:Cite press release</ref>

In September, 2020, Thomas Lee Partners and Frazier Healthcare acquired Adare Pharmaceuticals and turned into a contract development and manufacturing organization.<ref>Template:Cite news</ref>